Form 4: CARGO Therapeutics Director Disposes Shares Post-Merger

CARGO Therapeutics Director Krishnan Viswanadhan disposed of all beneficial ownership in the company following its acquisition by Concentra Biosciences.

Summary

• Director Krishnan Viswanadhan reported the disposition of all his beneficial ownership in CARGO Therapeutics, Inc.
• The disposition occurred on August 19, 2025, following the completion of a merger.
• CARGO Therapeutics, Inc. was acquired by Concentra Biosciences, LLC via a tender offer and subsequent merger.
• The tender offer, completed on August 18, 2025, was for $4.379 per share in cash plus one non-transferable contractual contingent value right (CVR).
• Outstanding stock options, including those held by Mr. Viswanadhan, became fully vested and were converted into cash and CVRs, or canceled if the exercise price was equal to or greater than the cash offer amount.

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, providing liquidity to shareholders and option holders. While it signifies the end of CARGO Therapeutics as an independent public entity, the transaction itself is a positive outcome for those holding the company's securities, especially given the cash component and potential upside from CVRs. The disposition of shares is an expected procedural outcome of the merger.

Positives

• The merger completion provides liquidity to shareholders and option holders.
• Option holders received cash and CVRs for their vested options, provided the exercise price was below the cash offer amount.

Negatives

• CARGO Therapeutics, Inc. is no longer an independent publicly traded entity, becoming a wholly-owned subsidiary of Concentra Biosciences, LLC.
• Options with an exercise price equal to or greater than the $4.379 cash amount were canceled for no consideration.

Risks

• Holders of Contingent Value Rights (CVRs) are subject to the terms and conditions of the CVR Agreement, meaning the value of the CVRs is contingent and not guaranteed.
• The reporting person is no longer subject to Section 16, implying a change in their relationship with the company post-merger.

Future Outlook

The filing indicates the completion of a merger, with CARGO Therapeutics, Inc. becoming a wholly-owned subsidiary of Concentra Biosciences, LLC. This implies that CARGO Therapeutics, Inc. will no longer operate as an independent public entity. The future value for former shareholders and option holders depends on the terms of the Contingent Value Rights Agreement.

Industry Context

This filing reflects a common trend of consolidation in the biotechnology or pharmaceutical industry, where larger entities acquire smaller, often clinical-stage, companies to expand their pipeline or acquire specific technologies. The use of CVRs is also a common mechanism in biotech mergers to bridge valuation gaps based on future clinical or regulatory milestones.

Comparison to Industry Standards

• The acquisition price of $4.379 per share plus a CVR is specific to this transaction and would need detailed financial models to compare against similar biotech acquisitions.
• The use of CVRs is a standard practice in biotech M&A, allowing for a portion of the acquisition value to be tied to future performance milestones, which can be seen in deals like the acquisition of Reata Pharmaceuticals by Biogen or the acquisition of Acceleron Pharma by Merck, both of which included CVR components.
• The immediate vesting of options upon merger completion is a standard provision in many change-of-control clauses within equity compensation plans.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, providing liquidity and potential future value.
• Option Holders: Received cash and CVRs for their vested options, or cancellation if out-of-the-money.
• Employees: Implied integration into Concentra Biosciences, LLC, with potential changes to employment terms or structure.
• Company (CARGO Therapeutics): No longer an independent public entity, now a subsidiary.

Next Steps

• Former shareholders and option holders will receive the cash consideration and CVRs as per the merger agreement.
• The value of the CVRs will depend on future events and milestones as defined in the CVR Agreement.
• CARGO Therapeutics, Inc. will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC.

Key Dates

Recommendation

The filing indicates the successful completion of a tender offer and subsequent merger, resulting in CARGO Therapeutics, Inc. becoming a wholly-owned subsidiary of Concentra Biosciences, LLC. As such, CARGO Therapeutics' common stock is no longer publicly traded, and existing shares have been converted into cash and contingent value rights (CVRs). Therefore, there is no longer a public market for the stock, and any recommendation to 'buy' or 'hold' is irrelevant. The transaction effectively represents a 'sell' event for previous shareholders as their equity has been exchanged.

Keywords

CARGO Therapeutics, CRGX, Concentra Biosciences, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Contingent Value Right, CVR, Stock Options